Carlos H. Timaran

Carlos H. Timaran

Auto-generated profile, based on publicly available information

Carlos H. Timaran

Division of Vascular and Endovascular Surgery, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2008 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
CTCarlos H. Timaran
Carlos H. Timaran
EREric B. Rosero
Eric B. Rosero
SSStephen T. Smith
Stephen T. Smith
RVR. James Valentine
R. James Valentine
JMJ. Gregory Modrall
J. Gregory Modrall
GCG. Patrick Clagett
G. Patrick Clagett

22 October 2024 in Circulation
Verified
Journal Article
Closed access
Nikolaos TsilimparisNikolaos Tsilimparis
Nikolaos Tsilimparis
RMRyan Gouveia e Melo
Ryan Gouveia e Melo
ETEmanuel R. Tenorio
Emanuel R. Tenorio
SSSalvatore Scali
Salvatore Scali
BMBernardo Mendes
Bernardo Mendes
GOGustavo S Oderich
Gustavo S Oderich
BACKGROUND: Physician modified endografts (PMEGs) have been widely used in the treatment of complex abdominal aortic aneurysm and thoracoabdominal aortic aneurysm, however, previous data are limited to small single center studies and robust data on safety and effectiveness of PMEGs are lacking. We aimed to perform an international multicenter study analyzing the outcomes of PMEGs in complex abdominal aortic aneurysms and thoracoabdominal aortic aneurysms. METHODS: An international multicenter single-arm cohort study was performed analyzing the outcomes of PMEGs in the treatment of elective, symptomatic, and ruptured complex abdominal aortic aneurysms and thoracoabdominal aortic aneurysms. Variables and outcomes were defined according to the Society for Vascular Surgery reporting standards. Device modification and procedure details were collected and analyzed. Efficacy outcomes included technical success and safety outcomes included major adverse events and 30-day mortality. Follow-up outcomes included reinterventions, endoleaks, target vessel patency rates and overall and aortic-related mortality. Multivariable analysis was performed aiming at identifying predictors of technical success, 30-day mortality, and major adverse events. RESULTS: Overall, 1274 patients were included in the study from 19 centers. Median age was 74 (IQR, 68–79), and 75.7% were men; 45.7% were complex abdominal aortic aneurysms, and 54.3% were thoracoabdominal aortic aneurysms; 65.5% patients presented electively, 24.6% were symptomatic, and 9.9% were ruptured. Most patients (83.1%) were submitted to a fenestrated repair, 3.6% to branched repair, and 13.4% to a combined fenestrated and branched repair. Most patients (85.8%) had ≥3 target vessels included. The overall technical success was 94% (94% in elective, 93.4% in symptomatic, and 95.1% in ruptured cases). Thirty-day mortality was 5.8% (4.1% in elective, 7.6% in symptomatic, and 12.7% in ruptured aneurysms). Major adverse events occurred in 25.2% of cases (23.1% in elective, 27.8% in symptomatic, and 30.3% in ruptured aneurysms). Median follow-up was 21 months (5.6–50.6). Freedom from reintervention was 73.8%, 61.8%, and 51.4% at 1, 3, and 5 years; primary target vessel patency was 96.9%, 93.6%, and 90.3%. Overall survival and freedom from aortic-related mortality was 82.4%/92.9%, 69.9%/91.6%, and 55.0%/89.1% at 1, 3, and 5 years. CONCLUSIONS: PMEGs were a safe and effective treatment option for elective, symptomatic, and ruptured complex aortic aneurysms. Long-term data and future prospective studies are needed for more robust and detailed analysis.

1 November 2011 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
CTCarlos H. Timaran
Carlos H. Timaran
EREric B. Rosero
Eric B. Rosero
AHAdriana Higuera
Adriana Higuera
AIAdriana Ilarraza
Adriana Ilarraza
JMJ. Gregory Modrall
J. Gregory Modrall
GCG. Patrick Clagett
G. Patrick Clagett

1 March 2009 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
DPDamon S. Pierce
Damon S. Pierce
EREric B. Rosero
Eric B. Rosero
JMJ. Gregory Modrall
J. Gregory Modrall
BABeverley Adams-Huet
Beverley Adams-Huet
RVR. James Valentine
R. James Valentine
CTCarlos H. Timaran
Carlos H. Timaran

15 June 2023 in Journal of Vascular Surgery
Verified
Journal Article
Open access
MAMohamed A. Abdelhalim
Mohamed A. Abdelhalim
ETEmanuel R. Tenorio
Emanuel R. Tenorio
GOGustavo S. Oderich
Gustavo S. Oderich
SHStephan Haulon
Stephan Haulon
GWGasper Warren
Gasper Warren
BMBijan Modarai
Bijan Modarai
This multicenter international study aimed to describe outcomes of fenestrated-branched endovascular aortic repairs (FB-EVAR) in a cohort of patients treated for chronic post-dissection thoracoabdominal aortic aneurysms (PD-TAAAs). We reviewed the clinical data of all consecutive patients treated by FB-EVAR for repair of Extent I-III PD-TAAAs in 16 centres from the United States and Europe (2008-2021). Data were extracted from institutional prospectively maintained databases and electronic patient records. All patients received off-the-shelf or patient-specific manufactured fenestrated-branched stent grafts. Endpoints were any cause mortality and major adverse events (MAEs) at 30-days, technical success, target artery (TA) patency, freedom from TA instability, minor (endovascular with <12Fr sheath) and major (open or ≥12Fr sheath) secondary interventions, patient survival and freedom from aortic-related mortality (ARM). A total of 246 patients (76% male; median age 67 years [IQR 61-73]) were treated for Extent I (7%), Extent II (55%) and Extent III (35%) PD-TAAAs by FB-EVAR. The median aneurysm diameter was 65mm [IQR 59-73]. Eighteen patients (7%) were octogenarians, 212 (86%) were American Society of Anaesthesiologists (ASA) class ≥3 and 21 (9%) presented with contained ruptured or symptomatic aneurysms. There were 917 renal-mesenteric vessels targeted by 581 fenestrations (63%) and 336 directional branches (37%), with a mean of 3.7 vessels per patient. Technical success was 96%. Mortality and rate of MAEs at 30-days was 3% and 28%, including disabling complications such as new-onset dialysis in 1%, major stroke in 1% and permanent paraplegia in 2%. Mean follow-up was 24 months. Kaplan-Meier (KM) estimated patient survival at 3- and 5-years was 79±6% and 65±10%. KM-estimated freedom from ARM was 95±3% and 93±5% at the same intervals. Unplanned secondary interventions were needed in 94 patients (38%), including minor procedures in 64 (25%) and major procedures in 30 (12%). There was one conversion to open surgical repair (<1%). KM-estimated freedom from any secondary intervention was 44±9% at 5-years. KM-estimated primary and secondary TA patency were 93±2% and 96±1% at 5-years, respectively. FB-EVAR for chronic PD-TAAAs was associated with high technical success and a low rate of mortality (3%) and disabling complications at 30-days. Although the procedure is effective in the prevention of ARM, patient survival was low at 5-years (65%), likely due to the significant comorbidities in this cohort of patients. Freedom from secondary interventions at 5-years was 44%, although most procedures were minor. The significant rate of reinterventions highlights the need for continued patient surveillance.

22 October 2024 in Circulation
Verified
Journal Article
Closed access
GOGustavo S Oderich
Gustavo S Oderich
YHYing Huang
Ying Huang
WHWilliam S. Harmsen
William S. Harmsen
ETEmanuel R. Tenorio
Emanuel R. Tenorio
ASAndres Schanzer
Andres Schanzer
SZSara L. Zettervall
Sara L. Zettervall
BACKGROUND: Fenestrated-branched endovascular aortic repair (FB-EVAR) has been used as a minimally invasive alternative to open surgical repair to treat patients with thoracoabdominal aortic aneurysms (TAAAs). The aim of this study was to evaluate aortic-related mortality (ARM) and aortic aneurysm rupture after FB-EVAR of TAAAs. METHODS: Patients enrolled in 8 prospective, nonrandomized, physician-sponsored investigational device exemption studies between 2005 and 2020 who underwent elective FB-EVAR of asymptomatic intact TAAAs were analyzed. Primary end points were ARM, defined as any early mortality (30 days or in hospital) or late mortality from aortic rupture, dissection, organ or limb malperfusion attributable to aortic disease, complications of reinterventions, or aortic rupture. Secondary end points were early major adverse events, TAAA life-altering events (defined as death, permanent spinal cord injury, permanent dialysis, or stroke), all-cause mortality, and secondary interventions. RESULTS: A total of 1109 patients were analyzed; 589 (53.1%) had extent I–III and 520 (46.9%) had extent IV TAAAs. Median age was 73.4 years (interquartile range, 68.1–78.3 years); 368 (33.2%) were women. Early mortality was 2.7% (n=30); congestive heart failure was associated with early mortality (odds ratio, 3.30 [95% CI, 1.22–8.02]; P =0.01). Incidence of early aortic rupture was 0.4% (n=4). Incidence of early major adverse events and TAAA life-altering events was 20.4% (n=226) and 7.7% (n=85), respectively. There were 30 late ARMs; 5-year cumulative incidence was 3.8% (95% CI, 2.6%–5.4%); older age and extent I–III TAAAs were independently associated with late ARM (each P <0.05). Fourteen late aortic ruptures occurred; 5-year cumulative incidence was 2.7% (95% CI, 1.2%–4.3%); extent I–III TAAAs were associated with late aortic rupture (hazard ratio, 5.85 [95% CI, 1.31–26.2]; P =0.02). Five-year all-cause mortality was 45.7% (95% CI, 41.7%–49.4%). Five-year cumulative incidence of secondary intervention was 40.3% (95% CI, 35.8%–44.5%). CONCLUSIONS: ARM and aortic rupture are uncommon after elective FB-EVAR of asymptomatic intact TAAAs. Half of the ARMs occurred early, and most of the late deaths were not aortic related. Late all-cause mortality rate and the need for secondary interventions were 46% and 40%, respectively, 5 years after FB-EVAR. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT02089607, NCT02050113, NCT02266719, NCT02323581, NCT00583817, NCT01654133, NCT00483249, NCT02043691, and NCT01874197.